Riverwater Partners LLC Purchases New Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Riverwater Partners LLC acquired a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the 3rd quarter, HoldingsChannel reports. The firm acquired 18,628 shares of the company’s stock, valued at approximately $161,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Delcath Systems by 31.0% in the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Delcath Systems in the second quarter valued at about $694,000. Shellback Capital LP purchased a new stake in Delcath Systems in the 2nd quarter valued at approximately $1,353,000. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems during the 2nd quarter worth approximately $370,000. Finally, Legato Capital Management LLC purchased a new position in shares of Delcath Systems during the 2nd quarter worth approximately $966,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Stock Down 4.7 %

NASDAQ:DCTH opened at $10.65 on Friday. Delcath Systems, Inc. has a 52-week low of $2.25 and a 52-week high of $11.74. The stock has a fifty day simple moving average of $9.34 and a 200-day simple moving average of $7.86. The company has a market capitalization of $295.92 million, a PE ratio of -4.02 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The business had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter last year, the business posted ($0.58) earnings per share. As a group, equities analysts anticipate that Delcath Systems, Inc. will post -1.67 earnings per share for the current year.

Analyst Ratings Changes

DCTH has been the topic of a number of analyst reports. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday. Craig Hallum initiated coverage on shares of Delcath Systems in a research report on Friday, June 28th. They set a “buy” rating and a $18.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Delcath Systems in a report on Friday, October 18th. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Delcath Systems has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.